Tristel plc
("Tristel" or the "Company")
Exercise of Share Options and Total Voting Rights
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a total of 15,500 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Group.
Application has been made to the London Stock Exchange for the 15,500 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 31 January 2024.
Total Voting Rights
After Admission, the total number of Ordinary Shares in issue will be 47,435,193 and the total number of voting rights will therefore be 47,435,193. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact:
Tristel plc | Tel: 01638 721 500 | |
| Paul Swinney, Chief Executive Officer | | |
| Liz Dixon, Chief Financial Officer | | |
|
| | |
| Walbrook PR Ltd | Tel: 020 7933 8780 or tristel@walbrookpr.com | |
| Paul McManus | Mob: 07980 541 893 | |
| Alice Woodings | Mob: 07407 804 654 | |
| Charlotte Edgar | Mob: 07884 664 686 | |
| | | |
| Cavendish Capital Markets Limited | Tel: 020 7220 0500 | |
| Geoff Nash/Charlie Beeson (Corporate Finance) | | |
| Sunila de Silva (ECM) | | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
